Drugs / NAVARIXIN ANHYDROUS
NAVARIXIN ANHYDROUS
also known as
Navarixin · SCH527123 · MK-7123 · MK-527123 · MK-7123 MONOHYDRATE · Navarixin monohydrate · Navarixina · Navarixine · +2 more
Small molecule targets CXCR1, CXCR2 via inhibition
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01068145 | Feb 2010 → Mar 2011 | chronic obstructive pulmonary disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT03473925 | Apr 2018 → May 2021 | colorectal cancer, non-small cell lung carcinoma, prostate carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT01006616 | Oct 2009 → Mar 2011 | chronic obstructive pulmonary disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00688467 | Jun 2008 → Mar 2009 | asthma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00632502 | May 2008 → Feb 2009 | asthma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00684593 | Jun → Oct 2007 | psoriasis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00441701 | Dec 2006 → Oct 2008 | chronic obstructive pulmonary disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01006161 Comparator | Jan 2010 → Aug 2012 | asthma | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NAVARIXIN ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL216981 ↗ |
| Known as | MK-527123 | “To evaluate the effect of navarixin (MK-527123, SCH 527123) treatment on allergen-induced late asthmatic response (LAR) in participants with mild asthma.” NCT00688467 ↗ |
| Known as | MK-7123 | “Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)” NCT00441701 ↗1“Navarixin (SCH 527123, MK-7123) is an antagonist of the cysteine-X-cysteine chemokine receptor 2 (CXCR2) and is thought to reduce neutrophil migration to the diseased lung.” NCT01006616 ↗ |
| Known as | MK-7123 MONOHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL216981 ↗ |
| Known as | Navarixin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01006616 ↗ |
| Known as | Navarixin monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL216981 ↗ |
| Known as | Navarixina | ChEMBL registry synonym — accepted as the source's own label CHEMBL216981 ↗ |
| Known as | Navarixine | ChEMBL registry synonym — accepted as the source's own label CHEMBL216981 ↗ |
| Known as | PS-291822 | ChEMBL registry synonym — accepted as the source's own label CHEMBL216981 ↗ |
| Known as | SCH-527123 MONOHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL216981 ↗ |
| Known as | SCH527123 | “Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)” NCT00441701 ↗4“Navarixin (SCH 527123, MK-7123) is an antagonist of the cysteine-X-cysteine chemokine receptor 2 (CXCR2) and is thought to reduce neutrophil migration to the diseased lung.” NCT01006616 ↗ “SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects.” PMID 19643947 ↗ Jul 2009 |
| Action | Inhibit | “a selective CXCR2 receptor antagonist” PMID 22702508 ↗ Jul 20121“Interleukin-8 receptor A antagonist” CHEMBL216981 ↗ |
| Modality | Small molecule | — CHEMBL216981 ↗ |
| Route | Oral | “taken by mouth” NCT00632502 ↗ |
| Target | CXCR1 | “Interleukin-8 receptor A antagonist” CHEMBL216981 ↗ |
| Target | CXCR2 | “a selective CXCR2 receptor antagonist” PMID 22702508 ↗ Jul 2012 |